Pirmdiena, 23. marts   Šī ir funkcionējoša termini.lza.lv versija. Apmeklējiet arī Latvijas Nacionālo terminoloģijas portālu.
  Sākumlapa
  Terminu datubāze
  Struktūra un principi
  Apakškomisijas
  Sēdes
  Lēmumi
  Protokoli
  Vēstules
  Publikācijas
  Konsultācijas
  Vārdnīcas
  EuroTermBank
  Par portālu
  Kontakti
  Resursi internetā
  «Terminoloģijas Jaunumi»
  Atbalstītāji
  Notikumi
LZA TK termini atrodami Akadēmiskajā terminu datubāzē AkadTerm

Vēlaties portāla jaunumus
saņemt pa e-pastu?
Norādiet savu adresi:

Pakalpojumu nodrošina FeedBlitz

AkadTerm – plašākā latviešu terminu datubāze
 Palīdzība
Izmantojiet zvaigznīti * vārda daļu meklēšanai (piemēram, dator* vai *pratība)
Nozares:
Kolekcijas:
Jūs meklējāt R
Atrasti 103 termini

▪ {(S)-[(R)-2-methyl-1-propionyloxypropoxy](4-phenylbutyl)phosphinoyl}acetic acid
▪ (2S)-N-[(R)-1-(1,3-benzodioxol-5-yl)butyl]-3,3-diethyl-2-{4-[(4-methylpiperazin-1-yl)carbonyl]phenoxy}-4-oxoazetidine-1-carboxamide
▪ 3-acetoxymethyl-7-[(R)-2-formyloxy-2-phenylacetamido]-3-cephem-4-carboxylic acid
▪ (3S,4R)-3-[(R)-1-(tert-butyldimethylsilyloxy)ethyl]-4-[(1R,3S)-3-methoxy-2-oxocyclohexyl]azetidin-2-one
▪ (3S,4R)-4-acetoxy-3-[(R)-1-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-one
▪ (3S,4S)-3-hexyl-4-[(R)-2-(hydroxytridecyl)]oxetan-2-one
▪ 4-nitrobenzyl (4R,5R,6S)-3-(diphenoxyphosphoryloxy)-6-[(R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
▪ 4-tert-butylbenzyl 2-{(2R,3S)-3-[(R)-1-(tert-butyldimethylsilyloxy)ethyl]-2-[(1R,3S)-3-methoxy-2-oxocyclohexyl]-4-oxoazetidin-1-yl}-2-oxoacetate
▪ 5-bromo-3-[(R)-1-methylpyrrolidin-2-ylmethyl]indole
▪ 5-[(R)-(2-aminopropyl)]-2-methoxybenzenesulfonamide
▪ 7-[(R)-amino(phenyl)acetamido]-3-methyl-3-cephem-4-carboxylic acid
▪ A/R
▪ A&R
▪ aeronautical mobile (R) service
▪ aeronautical safety type (AM(R)S, AMS(R)S, ARNS) spectrum
▪ AMS(R)S
▪ arms lateral L (R)
▪ bis[(isopropyloxycarbonyloxy)methyl [(R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methylphosphonate
▪ B.R. No.
▪ Common European Data Space for R&I
▪ ethyl (R)-2-hydroxy-4-phenylbutyrate
▪ EU R&I partnership
▪ F.O.R. price
▪ F.R. No.
▪ Global AMR R&D Hub
▪ I+R Directive
▪ intramural expenditure on R&D
▪ intramural R&D expenditure
▪ kick R leg forward
▪ KR&R
▪ low R&I performing country
▪ methyl (R)-3-hydroxybutyrate
▪ M.O.R.
▪ N-[(R)-2-({(R)-2-[(2-adamantyloxycarbonyl)amino]-3-(1H-indol-3-yl)-2-methyl-1-oxopropyl}amino)-1-phenylethyl]succinamic acid
▪ N-[(R)-9-methyl-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1-hi]indol-3-yl]isonicotinamide
▪ O/R address
▪ O/R name
▪ Ocean R&I Strategy
▪ outer cross-seat on the L/R thigh
▪ P&R policy
▪ P+R
▪ p-nitrobenzyl (2R,5R,6S)-6-[(R)-1-hydroxyethyl]-3,7-dioxo-1-azabicyclo[3.2.0]heptane-2-carboxylate
▪ ponceau 6 R
▪ potassium (R)-2-(4-hydroxyphenyl)-N-(3-methoxy-1-methyl-3-oxoprop-1-enyl)glycinate
▪ potassium (R)-N-(3-ethoxy-1-methyl-3-oxoprop-1-enyl)-2-phenylglycine
▪ potassium (R)-N-(3-methoxy-1-methyl-3-oxoprop-1-enyl)-2-phenylglycinate
▪ R
▪ R/T
▪ R/V
▪ R&B
▪ R&D
▪ R&D&I
▪ R&D&I Framework
▪ R&I
▪ R&R Guidelines
▪ R&D
▪ R& D activity
▪ R& D aid
▪ R & D costs
▪ R & D defence
▪ R&D expenditure
▪ R & D general public services
▪ R&D-intensive industry
▪ R & D public order and safety
▪ R & D Services
▪ R&TD Framework Programme
▪ (R)-1,2,3,4-tetrahydropapaverine hydrochloride
▪ (R)-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)propane-1,2-diol
▪ (R)-2-(3-benzoylphenyl)propionic acid
▪ (R)-2-(6-amino-9H-purin-9-yl)-1-methylethanol
▪ (R)-[2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methylphosphonic acid
▪ (R)-2-amino-2-ethylhexan-1-ol
▪ (R)-3-chloropropane-1,2-diol
▪ (R)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline
▪ (R)-alpha-(chlorocarbonyl)benzyl formate
▪ (R)-alpha-cyano-3-phenoxybenzyl(Z)-(lS,3S)-3-(2-chloro-3, 3, 3-trifluoropropenyl)-2,2-dimethylcyclopropane-carboxylate
▪ R arm
▪ R arm circle
▪ R arm circle inward (outward)
▪ R arm obliquely upward
▪ R arm to the side
▪ required subdivision index R
▪ Resistive (R), Capacitive (C) and Inductive (L) Circuits
▪ R.H.
▪ R (L) knee hang
▪ R.M.S.V.
▪ R.M.S. value
▪ (R)-N-(1-{3-[1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidyl]propyl}-4-phenyl-4-piperidyl)-N-methylacetamide hydrochloride
▪ R phrase
▪ (R)-p-mentha-1,8-diene
▪ R point
▪ (R)-propylene carbonate
▪ R.Q.
▪ S/R differences
▪ S.M.A.R.T. goal methodology
▪ sodium (R)-1-[(1-{3-[2-(7-chloro-2-quinolyl)vinyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl)thiomethyl]cyclopropylacetate
▪ sodium (R)-2-(4-hydroxyphenyl)-N-(3-methoxy-1-methyl-3-oxoprop-1-enyl)glycinate
▪ sodium (R)-N-(3-methoxy-1-methyl-3-oxoprop-1-enyl)-2-phenylglycinate
▪ speculative R&D
▪ squat support on the R/L leg
▪ S.R.F.
▪ T.C.R. No.
▪ total intramural R&D expenditure
  1. EN pricing of medicines (IETEICAMS); pharmaceutical pricing policy (PIEĻAUJAMS); pharmaceutical pricing and reimbursement (PIEĻAUJAMS); pricing and reimbursement of medicinal products (PIEĻAUJAMS); P&R policy (PIEĻAUJAMS); pharmaceutical reimbursement and pricing policy (PIEĻAUJAMS)
    LV zāļu cenu noteikšana (IETEICAMS); medikamentu cenu noteikšanas politika (PIEĻAUJAMS); medikamentu cenu noteikšana (PIEĻAUJAMS); zāļu kompensēšanas un cenu noteikšanas politika (PIEĻAUJAMS); medikamentu kompensēšana un cenu noteikšana (PIEĻAUJAMS); zāļu cenu politika (PIEĻAUJAMS); zāļu cenu noteikšana un kompensēšana (PIEĻAUJAMS); medikamentu kompensēšanas un cenu noteikšanas politika (PIEĻAUJAMS); medikamentu cenu politika (PIEĻAUJAMS); zāļu cenu noteikšanas politika (PIEĻAUJAMS)
    DE Preisfestsetzung für Medikamente (IETEICAMS); Preisfestsetzung und Kostenerstattung für Medikamente (PIEĻAUJAMS); Preisgestaltungs- und Kostenerstattungspolitik für Arzneimittel (PIEĻAUJAMS); Preisgestaltungspolitik für Arzneimittel (PIEĻAUJAMS); Preisfestsetzung und Kostenerstattung für Arzneimittel (PIEĻAUJAMS)
    FR fixation des prix des médicaments (IETEICAMS); fixation des prix et remboursement des produits pharmaceutiques (PIEĻAUJAMS); politique de fixation des prix et de remboursement des médicaments (PIEĻAUJAMS); politique de fixation des prix des produits pharmaceutiques (PIEĻAUJAMS)
    Definīcija: Act of setting a price for a medicine and covering the cost through a 3rd-party payer (such as social health insurance or the national health service).
    EuroVoc tēzaurs v4.23 © Eiropas Savienība, 2026
© 2005–2026 Latvijas Zinātņu akadēmija